Overview
Jordi Pardo-Lopez practices practicing medicine in Barcelona, Spain.
Their clinical expertise encompasses Multiple Myeloma, Plasmacytoma, POEMS Syndrome, and Relapsed Refractory Multiple Myeloma (RRMM).
They are actively involved in clinical research, co-authoring 9 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jordi Pardo-Lopez
Is Jordi Pardo-Lopez a top-rated expert for Multiple Myeloma?
MediFind is an objective health platform that identifies experts based on real-world data. Jordi Pardo-Lopez is classified as an Experienced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jordi Pardo-Lopez participate in research or clinical trials?
Yes. Jordi Pardo-Lopez has published 9 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Jordi Pardo-Lopez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Multiple MyelomaPardo-Lopez isExperienced. Learn about Multiple Myeloma.
- PlasmacytomaPardo-Lopez isExperienced. Learn about Plasmacytoma.
- POEMS SyndromePardo-Lopez isExperienced. Learn about POEMS Syndrome.
- Relapsed Refractory Multiple Myeloma (RRMM)